Literature DB >> 22245244

Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.

J H Foley1, L Ferris, K E Brummel-Ziedins.   

Abstract

Many studies have shown that unregulated or excessive thrombin formation is potentially a cause of thrombosis; however, studies examining processes that contribute to fibrin stabilization in individuals predisposed to thrombosis are limited. In this study, we investigate a family with familial thrombosis via type IIb protein C (PC) deficiency. Using contact pathway inhibited whole blood, thrombin generation, fibrin clot formation and factor (f)XIII activation were monitored over time in control (n=5) and PC deficient (n=4, 34 - 69% PC by activity) subjects. The dynamics of thrombin generation varied significantly with the time required to reach the maximal rate of thrombin-antithrombin formation being much shorter in PC deficiency (5.8 ± 0.4 minutes) than in controls (9.7 ± 0.4 minutes; p < 0.001). PC deficient clots were significantly heavier than control clots (p < 0.001) and this difference could not be contributed exclusively to differences in fibrinogen levels between groups. FXIII was consumed faster in PC deficient subjects (23.7 ± 2.0 nM/minute) than in controls (5.1 ± 1.5 nM/minute; p < 0.0001) suggesting increased fXIII activation and incorporation of fXIIIa substrates into the clot. In plasma, the clot lysis time was increased in PC deficiency by both TAFIa dependent and independent mechanisms. Since PC deficient clots are both denser and show a greater degree of resistance to fibrinolysis, these clots would likely resist fibrinolysis and potentiate fibrin deposition observed in thrombosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245244      PMCID: PMC3729219          DOI: 10.1016/j.thromres.2011.12.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  27 in total

Review 1.  Factor XIII: structure, activation, and interactions with fibrinogen and fibrin.

Authors:  L Lorand
Journal:  Ann N Y Acad Sci       Date:  2001       Impact factor: 5.691

2.  A simple method for the preparation of homogeneous phospholipid vesicles.

Authors:  Y Barenholz; D Gibbes; B J Litman; J Goll; T E Thompson; R D Carlson
Journal:  Biochemistry       Date:  1977-06-14       Impact factor: 3.162

3.  The identification of isopeptide crosslinks in insoluble fibrin.

Authors:  S Matacić; A G Loewy
Journal:  Biochem Biophys Res Commun       Date:  1968-02-26       Impact factor: 3.575

4.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.

Authors:  N L Esmon; W G Owen; C T Esmon
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

5.  Hageman factor fragment inhibitor in corn seeds: purification and characterization.

Authors:  Y Hojima; J V Pierce; J J Pisano
Journal:  Thromb Res       Date:  1980-10-15       Impact factor: 3.944

6.  Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease.

Authors:  Joseph D Mills; Robert A S Ariëns; Michael W Mansfield; Peter J Grant
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

7.  The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.

Authors:  R A Ariëns; H Philippou; C Nagaswami; J W Weisel; D A Lane; P J Grant
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

9.  Thrombin functions during tissue factor-induced blood coagulation.

Authors:  Kathleen E Brummel; Sara G Paradis; Saulius Butenas; Kenneth G Mann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

View more
  5 in total

Review 1.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 2.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

3.  Platelets do not express the oxidized or reduced forms of tissue factor.

Authors:  Beth A Bouchard; Matthew T Gissel; Matthew F Whelihan; Kenneth G Mann; Saulius Butenas
Journal:  Biochim Biophys Acta       Date:  2013-12-19

4.  Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.

Authors:  Matthew Gissel; Thomas Orfeo; Jonathan H Foley; Saulius Butenas
Journal:  Thromb Res       Date:  2012-08-27       Impact factor: 3.944

5.  In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus.

Authors:  Kathleen E Brummel-Ziedins; Matthew Gissel; Jacqueline Neuhaus; Álvaro H Borges; David R Chadwick; Sean Emery; James D Neaton; Russell P Tracy; Jason V Baker
Journal:  Res Pract Thromb Haemost       Date:  2018-09-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.